4/3
08:42 am
mtnb
Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]
High
Report
Matinas BioPharma Prices $10 Million Registered Direct Offering [Yahoo! Finance]
4/3
08:30 am
mtnb
Matinas BioPharma Prices $10 Million Registered Direct Offering
High
Report
Matinas BioPharma Prices $10 Million Registered Direct Offering
4/1
02:34 pm
mtnb
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
High
Report
Matinas BioPharma Holdings, Inc. (AMEX:MTNB) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/27
04:09 pm
mtnb
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
Medium
Report
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update [Yahoo! Finance]
3/27
04:05 pm
mtnb
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
Medium
Report
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
3/25
08:06 am
mtnb
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation [Yahoo! Finance]
Medium
Report
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation [Yahoo! Finance]
3/25
08:00 am
mtnb
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Low
Report
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
3/22
09:19 am
mtnb
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response [Yahoo! Finance]
High
Report
Three Patients with Invasive Fusarium Infection in Matinas BioPharma's Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response [Yahoo! Finance]
3/22
09:15 am
mtnb
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
Low
Report
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete Clinical Response
3/22
06:36 am
mtnb
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards [Yahoo! Finance]
Medium
Report
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards [Yahoo! Finance]
3/22
06:30 am
mtnb
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
Medium
Report
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
2/26
08:18 am
mtnb
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution [Yahoo! Finance]
Medium
Report
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution [Yahoo! Finance]
2/26
08:00 am
mtnb
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
High
Report
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access Program, Including Multiple Patients with Complete Clinical Resolution
2/20
07:46 am
mtnb
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis [Yahoo! Finance]
Low
Report
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis [Yahoo! Finance]
2/20
07:30 am
mtnb
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis
High
Report
Matinas BioPharma Successfully Reaches Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis